6 completed, 3 recruiting, 3 terminated, 2 active not recruiting. 9 Phase 2, 2 Early Phase 1, 2 Not applicable, 1 Phase 1, 1 Phase 3.
Follow BCLC Stage C Hepatocellular Carcinoma: new trials by email Literature Review of BCLC Stage C Hepatocellular Carcinoma trials Research Report on BCLC Stage C Hepatocellular Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| SBRT Plus Systemic Therapy vs Systemic Therapy Alone in BCLC C Hepatocellular Carcinoma Systemic therapy, Radiotherapy - Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma | Phase 2 | Suspended | Shandong Cancer Hospital and Institute | 184 | 2025-11-30 | 2026-10-15 |
| HAIC in Combination with PD-1 Inhibitors and Lenvatinib for Intermediate and Advanced HCC After the Failure of Systemic Therapy Recommended by BCLC hepatic artery infusion chemotherapy, Lenvatinib + PD-1 monoclonal antibody - BCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma | Recruiting | First Hospital of China Medical University | 84 | 2024-09-16 | 2024-10-08 | |
| Infusional FOLFOX Plus Camrelizumab and Apatinib vs HAIC-FOLFOX Plus Camrelizumab and Apatinib for Advanced HCC intravenous FOLFOX7 plus Camrelizumab and apatinib, HAIC-FOLFOX plus Camrelizumab and apatinib - BCLC Stage C Hepatocellular Carcinoma, Chemotherapy Effect | Phase 3 | Recruiting | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 262 | 2023-07-01 | 2025-12-03 |
| Liver Cancer and Immunotherapy in the Liquid Biopsy Era Liquid Biopsy - Hepatocellular Carcinoma, BCLC Stage B Hepatocellular Carcinoma | Not applicable | Recruiting | University Hospital, Montpellier | 60 | 2023-06-28 | 2025-07-10 |
| A Phase II Study of Nivolumab + Ipilimumab in Advanced HCC Patients Who Have Progressed on First Line Atezolizumab + Bevacizumab Ipilimumab, Nivolumab - BCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma | Phase 2 | Terminated | Academic and Community Cancer Research United | 15 | 2023-01-19 | 2026-08-04 |
| Yttrium Y 90 Glass Microspheres, Atezolizumab, and Cabozantinib for the Treatment of Unresectable or Locally Advanced Hepatocellular Carcinoma Atezolizumab, Biopsy, Cabozantinib S-malate - BCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma | Phase 2 | Withdrawn | OHSU Knight Cancer Institute | 2022-12-10 | 2022-12-14 | |
| BOLD MRI and FMISO PET for the Assessment of Hypoxic Tumor Microenvironment in Patients with Oligometastatic Liver Cancer Undergoing Yttirum-90 Selective Internal Radiation Therapy 18F-Fluoromisonidazole, Biopsy, Dynamic Contrast-Enhanced Magnetic Resonance Imaging - BCLC Stage a Hepatocellular Carcinoma, BCLC Stage B Hepatocellular Carcinoma | Early Phase 1 | Completed | Emory University | 9 | 2022-04-28 | 2025-03-13 |
| BO-112 and Pembrolizumab for the Treatment of PD-1/PD-L1 Refractory Liver Cancer Nanoplexed Poly I:C BO-112, Pembrolizumab - Advanced Hepatocellular Carcinoma, BCLC Stage B Hepatocellular Carcinoma | Early Phase 1 | Terminated | Jonsson Comprehensive Cancer Center | 1 | 2021-10-13 | 2023-03-24 |
| TACE+Tilelizumab+Sorafenib in the Treatment of BCLC Stage C HCC TACE, Tilelizumab, Sorafenib - BCLC Stage C Hepatocellular Carcinoma | Phase 2 | Unknown | First Affiliated Hospital of Zhejiang University | 20 | 2021-08-20 | 2023-02-16 |
| Futibatinib and Pembrolizumab for Treatment of Advanced or Metastatic FGF19 Positive BCLC Stage A, B, or C Liver Cancer Futibatinib, Pembrolizumab, Quality-of-Life Assessment - Advanced Hepatocellular Carcinoma, BCLC Stage A Hepatocellular Carcinoma | Phase 2 | Completed | Mayo Clinic | 14 | 2021-08-17 | 2025-11-18 |
| Durvalumab and Tremelimumab After Radioembolization for the Treatment of Unresectable, Locally Advanced Liver Cancer Durvalumab, Tremelimumab - BCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma | Phase 1 | Active not recruiting | City of Hope Medical Center | 25 | 2021-08-03 | 2026-04-20 |
| Selective Internal Radiation Therapy (SIRT) Using SIR-Spheres® Y-90 Resin Microspheres on DoR & ORR in Unresectable Hepatocellular Carcinoma Patients Resin microspheres containing yttrium-90 (Y-90) - Unresectable Hepatocellular Carcinoma, BCLC Stage A Hepatocellular Carcinoma | Not applicable | Active not recruiting | Sirtex Medical | 100 | 2021-05-28 | 2026-02-03 |
| Cabozantinib and Pembrolizumab for the First-Line Treatment of Advanced Liver Cancer Cabozantinib S-malate, Pembrolizumab - Advanced Hepatocellular Carcinoma, BCLC Stage B Hepatocellular Carcinoma | Phase 2 | Terminated | University of Washington | 2 | 2021-04-20 | 2023-04-05 |
| HAIC in Combination With PD-1 Inhibitors and Lenvatinib for High Tumor Burden Advanced HCC (CHANCE2416) hepatic artery infusion chemotherapy, Lenvatinib + PD-1 monoclonal antibody - HCC - Hepatocellular Carcinoma, Hepatic Arterial Infusion Chemotherapy | Completed | First Hospital of China Medical University | 244 | 2021-01-01 | 2026-01-27 | |
| The Safety and Efficacy of Thermal Ablation Combined With Apatinib and Carilimub for Advanced Liver Cancer Apatinib Mesylate - BCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma | Phase 2 | Unknown | Chinese PLA General Hospital | 90 | 2019-11-01 | 2019-12-19 |
| Pembrolizumab (MK-3475) in Hepatocellular Carcinoma Elbasvir/Grazoprevir, Laboratory Biomarker Analysis, Pembrolizumab - BCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma | Phase 2 | Completed | M.D. Anderson Cancer Center | 15 | 2016-12-09 | 2025-07-15 |
| Using Machine Learning to Identify Responders to TACE or HAIC for uHCC Transarterial chemoembolization (TACE), hepatic arterial infusion chemotherapy (HAIC) - Unresectable Hepatocellular Carcinoma (HCC), BCLC Stage B Hepatocellular Carcinoma | Completed | First Affiliated Hospital, Sun Yat-Sen University | 3000 | 2015-01-01 | 2026-01-26 | |
| Sorafenib Tosylate and Yttrium Y 90 Glass Microspheres in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery Laboratory Biomarker Analysis, Quality-of-Life Assessment, Sorafenib - Advanced Adult Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma | Phase 2 | Completed | M.D. Anderson Cancer Center | 40 | 2013-09-13 | 2021-12-30 |
Carcinoma, Hepatocellular (13) · Hepatitis C (1) · Liver Neoplasms (1) · Neoplasm Metastasis (1)
Digestive System Diseases (14) · Digestive System Neoplasms (14) · Liver Diseases (14) · Neoplasms (14) · Neoplasms by Site (14) · Adenocarcinoma (13) · Carcinoma (13) · Liver Neoplasms (13) · Neoplasms by Histologic Type (13) · Neoplasms, Glandular and Epithelial (13) · Blood-Borne Infections (1) · Communicable Diseases (1) · Flaviviridae Infections (1) · Hepatitis (1) · Hepatitis, Viral, Human (1)
pembrolizumab (4) · Biopsy (2) · Sorafenib (2) · apatinib (2) · cabozantinib (2) · camrelizumab (2) · lenvatinib (2) · BO-112 (1) · Blood Specimen Collection (1) · CTLA-4 Antigen (1) · Disulfides (1) · Immunoglobulin G (1) · Ipilimumab (1) · Liquid Biopsy (1) · Magnetic Resonance Spectroscopy (1)
First Hospital of China Medical University (2) · M.D. Anderson Cancer Center (2) · Academic and Community Cancer Research United (1) · Chinese PLA General Hospital (1) · City of Hope Medical Center (1) · Emory University (1) · First Affiliated Hospital of Zhejiang University (1) · First Affiliated Hospital, Sun Yat-Sen University (1) · Jonsson Comprehensive Cancer Center (1) · Mayo Clinic (1) · OHSU Knight Cancer Institute (1) · Shandong Cancer Hospital and Institute (1) · Sirtex Medical (1) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (1) · University Hospital, Montpellier (1)
United States (9) · China (7) · France (1)
Adel Kardosh, M.D., Ph.D. (1) · Ahmed O Kaseb (1) · Ahmed O Kaseb, MD (1) · Armeen Mahvash, M.D. (1) · Daneng Li (1) · Gentry George King (1) · Haibo Shao (1) · Jie Yu (1) · Jun-hui Sun, MD,PH.D (1) · Mehmet Akce (1) · Nguyen H. Tran, M.D. (1) · Nima Kokabi, MD, FRCPC (1) · Richard S Finn (1) · S. Cheenu Kappadath, Ph.D. (1)
PMID 34527608, PMID 35346070, PMID 40930561
P30CA015083 (1), P30CA016672 (1), P30CA033572 (1), P30CA138292 (1)